Experimental autoimmune encephalomyelitis (EAE) is the most commonly used
experimental model for the human inflammatory demyelinating disease, multiple sclerosis …

While no single model can exactly recapitulate all aspects of multiple sclerosis (MS), animal
models are essential in understanding the induction and pathogenesis of the disease and to …

Background and Purpose Sphingosine1‐phosphate (S1P) receptors mediate multiple
events including lymphocyte trafficking, cardiac function, and endothelial barrier integrity …

Multiple sclerosis (MS) is a multifocal demyelinating disease of the central nervous system
(CNS) leading to the progressive destruction of the myelin sheath surrounding axons. It can …

The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory
drug, has opened up new approaches to the treatment of multiple sclerosis, the most …

Fingolimod (FTY720) is a first-in-class orally bioavailable compound that has shown efficacy
in advanced clinical trials for the treatment of multiple sclerosis (MS). In vivo, fingolimod is …

BACKGROUND AND PURPOSE BAF312 is a next‐generation sphingosine 1‐phosphate
(S1P) receptor modulator, selective for S1P1 and S1P5 receptors. S1P1 receptors are …

Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-
class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral …

Fingolimod is the first oral disease-modifying therapy approved for relapsing forms of
multiple sclerosis (MS). Following phosphorylation in vivo, the active agent, fingolimod …

Until recently, all approved multiple sclerosis (MS) disease treatments were administered
parenterally. Oral fingolimod was approved in September 2010 by the US Food and Drug …